Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.46 |
| ▸ | INSR | P06213 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 5/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5612905 | 0.86 | METAP2 (0.61) | METAP2FFAR1KDM4ENPC1ALDH1A1 | |
| SCHEMBL5613146 | 0.81 | PIK3CA (0.45) | METAP2ALDH1A1 | |
| SCHEMBL1249206 | 0.79 | PFKFB3 (0.60) | METAP2INSRIGF1RPFKFB3ALDH1A1 | |
| SCHEMBL5612898 | 0.78 | HPGD (0.53) | METAP2CLK1KDM4ENPC1ALDH1A1 | |
| SCHEMBL949314 | 0.78 | INSR (0.44) | METAP2INSRIGF1RNOS1FFAR1 | |
| SCHEMBL5612904 | 0.76 | BRD4 (0.50) | METAP2KDM4E | |
| SCHEMBL5020121 | 0.76 | INSR (0.44) | METAP2INSRIGF1RNOS1FFAR1 | |
| SCHEMBL6161279 | 0.75 | CYP1A2 (0.50) | KDM4ENPC1ALDH1A1HPGDRAB9A | |
| SCHEMBL6170747 | 0.75 | CYP1A2 (0.52) | KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL6165618 | 0.74 | INSR (0.46) | INSRIGF1RKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004116-A1 | 1H-1,2,3-triazol-4-yl derivatives; antiangiogenesis agents | SMITHKLINE BEECHAM CORPORATION | 2005-01-06 | — | — | US | claimed |
| US-20030220371-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2003-11-27 | — | — | US | claimed |
| EP-1274424-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2003-09-17 | — | — | EP | claimed |
| EP-1274424-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-15 | — | — | EP | claimed |
| WO-2001078723-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-25 | — | — | WO | claimed |
| US-20070077641-A1 | Methionine aminopeptidase and methods of use | PALMER LESLIE | 2007-04-05 | — | — | US | disclosed |
| EP-1624849-A2 | METHIONINE AMINOPEPTIDASE AND METHODS OF USE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-15 | — | — | EP | disclosed |
| WO-2005016237-A2 | METHIONINE AMINOPEPTIDASE AND METHODS OF USE | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050004116-A1 | 1H-1,2,3-triazol-4-yl derivatives; antiangiogenesis agents | SMITHKLINE BEECHAM CORPORATION | 2005-01-06 | — | — | US | disclosed |
| US-20030220371-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2003-11-27 | — | — | US | disclosed |
| EP-1274424-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2003-09-17 | — | — | EP | disclosed |
| EP-1274424-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001078723-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004116-A1 | 1H-1,2,3-triazol-4-yl derivatives; antiangiogenesis agents | METAP1, METAP2, DNPEP | METAP2 2/4885INSR 1611/4885IGF1R 263/4885 |
| US-20030220371-A1 | Compounds and methods | METAP2, METAP1, DNPEP | METAP2 1/4885INSR 2433/4885IGF1R 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.